治疗双抗性慢性淋巴细胞白血病-一个未满足的临床需求
Przemysław Zygmunciak1, Tadeusz Robak2,3, Bartosz Puła1
1Department of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.
International journal of molecular sciences
|February 10, 2024
概括
针对B细胞淋巴瘤 (BCL-2) 和布鲁顿淋巴瘤的慢性淋巴细胞白血病 (CLL) 治疗方法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性淋巴细胞白血病 (CLL) 的治疗已经通过向治疗得到了进展.
- B细胞淋巴瘤 (BCL-2) 和布鲁顿激酶 (BTK) 抑制剂是CLL的关键策略.
- 停止治疗的原因是耐药性,不良反应和里希特转变.
研究的目的:
- 探索CLL中对ibrutinib和venetoclax的耐药性机制.
- 审查双抗性CLL患者的新型治疗策略.
- 解决BTK和BCL-2抑制剂治疗进展的患者所面临的挑战.
主要方法:
- 关于对易布鲁替尼和venetoclax的耐药性机制的文献综述.
- 对双重耐火性CLL新兴治疗方法的分析.
- 综合当前关于管理先前暴露于BTK和BCL-2抑制剂的患者的数据.
主要成果:
- 确定了对ibrutinib和venetoclax的关键耐药性途径.
- 突出了双重耐火性CLL日益增长的临床挑战.
- 总结了这个患者群体有前途的研究疗法.
结论:
- 了解耐药机制对于克服CLL治疗失败至关重要.
- 需要创新疗法来管理越来越多的耐标准向药物耐药患者.
- 对双抗性CLL进行进一步的新组合和连续治疗的研究是有必要的.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)

